ABSTRACT
KEY POINTS ■ Lipid-lowering monotherapy is well tolerated and is associated with a low frequency of adverse
events. ■ However, many patients with lipid-lowering therapy do not reach the current treatment goals
on the lipid profile. Therefore, a combination therapy between classes of lipid-lowering agents is strongly recommended by the current guidelines.
